AG-213
| 规格 | 价格 | 货期 | 数量 |
|---|---|---|---|
| 5mg | ¥1083.00 | 10-15工作日发货 | |
| 10mg | ¥2058.00 | 10-15工作日发货 | |
| 25mg | ¥4279.00 | 10-15工作日发货 | |
| 50mg | ¥6500.00 | 10-15工作日发货 |
特色产品
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰
产品描述
AG-213 is an inhibitor of protein tyrosine kinases (PTKs) and epidermal growth factor (EGF) receptor kinase [1,2].
Protein tyrosine kinases (PTKs) have been involved in regulating cell proliferation, cell differentiation, and signaling processes in the immune system. Dysfunction of protein tyrosine kinases result in inflammatory responses and diseases including cancer, atherosclerosis, and psoriasis [3]. The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein. Activation of EGFR results in autophosphorylation of receptor tyrosine kinase and has been involved in regulating cellular proliferation, differentiation, and survival. Overexpression of EGFR has been identified in a variety of tumor cell lines and has been associated with poor prognosis and decreased survival [4].
Administration of AG 213(100 μM) interfered with HUVEC focal adhesion and stress fiber formation. Pretreatment of monolayers with AG 213 (25, 50, and 75 μM) produced partial and incremental inhibition of HUVEC migration. In HUVEC, treatment with tyrphostin AG 213 (25 and 50 μM) demonstrated partial inhibition of stress fiber assembly compared with cells treated with 100 μM AG 213 [1]. AG 213 inhibited adhesion-associated tyrosine phosphorylation of pp125FAK activity in HUVEC [1]. AG-213 inhibited the activity of epidermal growth factor (EGF) receptor kinase with an IC50 value of 2.4 μM in the human epidermoid carcinoma cell line A431 [2].
References:
[1] Romer L H, McLean N, Turner C E, et al. Tyrosine kinase activity, cytoskeletal organization, and motility in human vascular endothelial cells[J]. Molecular Biology of the Cell, 1994, 5(3): 349-361.
[2] Gazit A, Yaish P, Gilon C, et al. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors[J]. Journal of medicinal chemistry, 1989, 32(10): 2344-2352.
[3] Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development[J]. Science, 1995, 267(5205): 1782.
[4] Herbst R S. Review of epidermal growth factor receptor biology[J]. International Journal of Radiation Oncology Biology Physics, 2004, 59(2): S21-S26.
产品性质
| 物理外观 | A crystalline solid |
| CAS号 | 122520-86-9 |
| 分子式 | C10H8N2O2S |
| 分子量 | 220.2 |
| 小分子别名 | Tyrphostin AG213 |
| 化学名称 | 2-cyano-3-(3,4-dihydroxyphenyl)-2E-propenethioamide |
| 溶解度 | ≤10mg/ml in ethanol;20mg/ml in DMSO;15mg/ml in dimethyl formamide |
| SMILES | NC(/C(\C#N)=C/c(cc1)cc(O)c1O)=S |
| 存储条件 | -20°C |
| 运输条件 | 蓝冰 |



沪公网安备 31011002003500